First-line cisplatin,docetaxel,and cetuximab for patients with recurrent or metastatic head and neck cancer:A multicenter cohort study

作     者：Agustin Falco Mariano Leiva Albano Blanco Guido Cefarelli Andres Rodriguez Juan Melo Federico Cayol Manglio Miguel Rizzo Alejandro Sola Hernan Rodriguez Montani Matias Chacon Diego Enrico Federico Waisberg 

作者机构：Department of Medical OncologyHead and Neck UnitAlexander Fleming Cancer InstituteBuenos Aires 1428Argentina Department of Medical OncologyAlexander Fleming Cancer InstituteBuenos Aires 1426Argentina Department of Medical OncologyHospital Italiano de Buenos AiresBuenos Aires 1199Argentina Department of Medical OncologyHospital Universitario AustralPilar 1629Argentina Department of Medical OncologyFundación Centro Oncológico de Integración RegionalMendoza 5500Argentina Department of Medical OncologyHospital Italiano RosarioSanatorio de la MujerRosario 2001Argentina 

出 版 物：《World Journal of Clinical Oncology》 (世界临床肿瘤学杂志（英文版）)

年 卷 期：2022年第13卷第2期

页      面：147-158页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：financially supported by Merck KGaA Darmstadt German 

主　　题：Recurrent and/or metastatic head and neck cancer TPEx schema Cetuximab Docetaxel Cisplatin First-line 

摘      要：BACKGROUND The targeted therapy cetuximab[directed at the epidermal growth factor receptor(EGFR)]in combination with 5-fluorouracil and platinum-based chemotherapy(the EXTREME regimen)has shown substantial efficacy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck(R/M SCCHN).Thus,this scheme has been established as the preferred first-line option for these ***,more recently,a new strategy combining platinum,taxanes,and cetuximab(the TPEx regimen)has demonstrated similar efficacy with a more favorable toxicity profile in clinical *** To evaluate the safety and efficacy of the TPEx scheme as first-line therapy in advanced SCCHN in a multicenter cohort *** This retrospective multicenter cohort study included patients with histologically confirmed recurrent or metastatic SCCHN treated with first-line TPEx at five medical centers in Argentina between January 1,2017 and April 31,*** consisted of four cycles of docetaxel,cisplatin,and cetuximab followed by cetuximab maintenance *** outcomes and toxicity profiles were collected from medical *** response was assessed by the investigator in accordance with Response Evaluation Criteria in Solid Tumors(version 1.1).Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events(version 4.0).RESULTS Twenty-four patients were *** median age at diagnosis was 58 years(range:36-77 years).The majority of patients(83.3%)received at least four chemotherapy cycles in the initial *** the included group,the overall response rate was 62.5%,and 3 patients achieved a complete response(12.5%).The median time to response was 2.4 mo[95% confidence interval(CI):1.3-3.5].With a median follow-up of 12.7 mo(95%CI:8.8-16.6),the median progression-free survival(PFS)was 6.9 mo(95%CI:6.5-7.3),and the overall survival rate at 12 mo was 82.4%.Patients with documented tumor response s